422 related articles for article (PubMed ID: 32882969)
21. Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector.
Guayasamin RC; Reynolds TD; Wei X; Fujiwara M; Robek MD
J Virol; 2014 Sep; 88(18):10909-17. PubMed ID: 25008938
[TBL] [Abstract][Full Text] [Related]
22. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow.
Breitbach CJ; Paterson JM; Lemay CG; Falls TJ; McGuire A; Parato KA; Stojdl DF; Daneshmand M; Speth K; Kirn D; McCart JA; Atkins H; Bell JC
Mol Ther; 2007 Sep; 15(9):1686-93. PubMed ID: 17579581
[TBL] [Abstract][Full Text] [Related]
23. Immune Consequences of in vitro Infection of Human Peripheral Blood Leukocytes with Vesicular Stomatitis Virus.
Tomczyk T; Wróbel G; Chaber R; Siemieniec I; Piasecki E; Krzystek-Korpacka M; Orzechowska BU
J Innate Immun; 2018; 10(2):131-144. PubMed ID: 29306950
[TBL] [Abstract][Full Text] [Related]
24. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.
Janelle V; Brassard F; Lapierre P; Lamarre A; Poliquin L
J Virol; 2011 Jul; 85(13):6513-20. PubMed ID: 21561919
[TBL] [Abstract][Full Text] [Related]
25. Cancer upregulated gene 2, a novel oncogene, confers resistance to oncolytic vesicular stomatitis virus through STAT1-OASL2 signaling.
Malilas W; Koh SS; Srisuttee R; Boonying W; Cho IR; Jeong CS; Johnston RN; Chung YH
Cancer Gene Ther; 2013 Feb; 20(2):125-32. PubMed ID: 23306614
[TBL] [Abstract][Full Text] [Related]
26. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
Nelson A; Gebremeskel S; Lichty BD; Johnston B
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
[TBL] [Abstract][Full Text] [Related]
27. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ
Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628
[TBL] [Abstract][Full Text] [Related]
28. Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?
Zhang Y; Nagalo BM
Front Immunol; 2022; 13():898631. PubMed ID: 35837384
[TBL] [Abstract][Full Text] [Related]
29. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ
J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
[TBL] [Abstract][Full Text] [Related]
31. Modulation of the tumor microenvironment by armed vesicular stomatitis virus in a syngeneic pancreatic cancer model.
Tang S; Shi L; Luker BT; Mickler C; Suresh B; Lesinski GB; Fan D; Liu Y; Luo M
Virol J; 2022 Feb; 19(1):32. PubMed ID: 35197076
[TBL] [Abstract][Full Text] [Related]
32. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
[TBL] [Abstract][Full Text] [Related]
33. A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.
Smith KER; Peng KW; Pulido JS; Weisbrod AJ; Strand CA; Allred JB; Newsom AN; Zhang L; Packiriswamy N; Kottke T; Tonne JM; Moore M; Montane HN; Kottschade LA; McWilliams RR; Dudek AZ; Yan Y; Dimou A; Markovic SN; Federspiel MJ; Vile RG; Dronca RS; Block MS
Front Immunol; 2023; 14():1279387. PubMed ID: 38022659
[TBL] [Abstract][Full Text] [Related]
34. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.
Betancourt D; Ramos JC; Barber GN
J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177
[TBL] [Abstract][Full Text] [Related]
35. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors.
Gao Y; Bergman I
J Virol; 2023 Jun; 97(6):e0037223. PubMed ID: 37199666
[TBL] [Abstract][Full Text] [Related]
36. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.
Peng KW; Myers R; Greenslade A; Mader E; Greiner S; Federspiel MJ; Dispenzieri A; Russell SJ
Gene Ther; 2013 Mar; 20(3):255-61. PubMed ID: 22476202
[TBL] [Abstract][Full Text] [Related]
37. Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers.
Fehl DJ; Ahmed M
Virus Res; 2017 Jan; 228():14-23. PubMed ID: 27865863
[TBL] [Abstract][Full Text] [Related]
38. Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands.
Ammayappan A; Peng KW; Russell SJ
J Virol; 2013 Dec; 87(24):13543-55. PubMed ID: 24089573
[TBL] [Abstract][Full Text] [Related]
39. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
40. mRNA cap methylation influences pathogenesis of vesicular stomatitis virus in vivo.
Ma Y; Wei Y; Zhang X; Zhang Y; Cai H; Zhu Y; Shilo K; Oglesbee M; Krakowka S; Whelan SP; Li J
J Virol; 2014 Mar; 88(5):2913-26. PubMed ID: 24371058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
